Skip to main navigation
Skip to main content
Skip to Footer

Navigate Novartis

Coronavirus

Global
- Novartis site directory

Our Company
Our Focus
Our Impact
Our Science
Careers

All News

Advanced Search Basic Search

From Date:

To Date:

Show:

All

Featured News

Media Releases

In the News

Stories

Statements

Pulse Updates

Filter By

2021

June

Media Release / Jun 18, 2021

New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

Featured News / Jun 16, 2021

Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)

In The News / Jun 16, 2021

Novartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happen

Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.

Media Release / Jun 11, 2021

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Featured News / Jun 10, 2021

Novartis Entresto® indicated for treatment of hypertension in China

Media Release / Jun 07, 2021

Novartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)

Media Release / Jun 06, 2021

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Media Release / Jun 04, 2021

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Media Release / Jun 04, 2021

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Media Release / Jun 03, 2021

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Search Results Navigation

Current page 1 of 5
Page 2 of 5
Page 3 of 5
Page 4 of 5
Page 5 of 5
…
Next page
Last page

Related Links

Stay Up-to-Date
We are inspiring our people
Malaria
Novartis SEC Filings

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

You are here

Home ›
Media

Novartis Global

Navigate Novartis
Contact Us
About Novartis
Our Portfolio
- Global Product Portfolio
- Global Clinical Pipeline
Careers
- Career Search

Connect with Novartis

twitter
linkedin
youtube
facebook
instagram

Novartis Site Directory

© 2021 Novartis AG

Terms of Use
Privacy Policy
Contact Us
Site Map
Cookie Settings

This site is intended for a global audience.